Thursday, 15 October 2026European Markets

BEVER HOLDING Stock Bearish Momentum With A 9% Slide So Far Today

Loading stream...

In unexpected financial news from the property sector, BEVER HOLDING (AEX-Index: BEVER.AS), a Dutch real estate company, has seen significant changes in its stock performance. The company's shares took an unanticipated downturn on the AEX-Index, which marks not just a minor hiccup, but the continuation of a worrying trend.

Stock Performance

The stock price of BEVER HOLDING declined by 9.09% to EUR3.00 at 14:07 EST on Wednesday, marking their fifth consecutive day of decline. This alarming trend led to an overall decrease of 0.93% on the AEX-Index to EUR772.56. Furthermore, BEVER HOLDING's stock price has been experiencing a steady decrease over time, as can be seen from its trading history. The company closed at EUR3.30 last time they traded, a steep 23.26% decrease from its 52-week high of EUR4.30.

Financial Health

BEVER HOLDING's financial health has been reflected in its stock performance. The company's trailing twelve-month earnings per share (EPS) is EUR-1.12, indicating negative profitability. Also noteworthy is the return on equity, which measures business profitability in relation to shareholders' equity. In BEVER HOLDING's case, it stands at -47.79% over the past twelve months.

Market Position

Currently, BEVER HOLDING's stock price falls below its 50-day moving average of EUR3.58 and 200-day moving average of EUR3.68. These figures indicate a potential bear market. However, even with today's decrease, the current pricing of the stock still remains higher than its 52-week low of EUR2.76.

A Word of Caution

Investors considering BEVER HOLDING should proceed with caution. Given the company's negative profitability metrics and the steadily declining trajectory of its stock price, close observation is necessary to spot any sudden movements or deviations from the expected trend. The current state of BEVER HOLDING calls for meticulous evaluation and risk assessment before making any investment decisions.

More news about BEVER HOLDING (BEVER.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com